Edesa Biotech (NASDAQ: EDSA) CEO adds 3,000 shares in open-market purchases

Rhea-AI Filing Summary

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported open-market purchases of company common shares. On March 2, 2026, he bought 2,000 common shares directly at $2.00 per share and an additional 1,000 common shares indirectly at $2.2796 per share through Pardeep Nijhawan Medicine Professional Corporation.

Following these transactions, direct holdings stood at 627,813 common shares. Indirectly, entities associated with him held 372,702 common shares at Pardeep Nijhawan Medicine Professional Corporation, 32,609 common shares at The New Nijhawan Family Trust 2015, 32,013 common shares at The Digestive Health Clinic Inc., and 53,104 common shares at 1968160 Ontario Inc. The report notes that he disclaims beneficial ownership of these indirect holdings except to the extent of his pecuniary interest.

Insider Trade Summary

Net Buyer: 3,000 shares ($6,280)

Net Buy 5 txns

Insider Nijhawan Pardeep

Role Chief Executive Officer

Bought 3,000 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	2,000	$2.00	$4K
Purchase	Common Shares	1,000	$2.2796	$2K
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 627,813 shares (Direct); Common Shares — 372,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation)

Footnotes (1)

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/02/2026		P		2,000	A	$2	627,813	D
Common Shares	03/02/2026		P		1,000	A	$2.2796	372,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(1)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(1)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160 Ontario Inc.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Edesa Biotech (EDSA) report for Pardeep Nijhawan?

Edesa Biotech reported that CEO and director Pardeep Nijhawan bought 3,000 common shares on March 2, 2026. He purchased 2,000 shares directly and 1,000 shares indirectly through Pardeep Nijhawan Medicine Professional Corporation in open-market transactions.

At what prices did the Edesa Biotech CEO buy EDSA shares on March 2, 2026?

On March 2, 2026, the CEO bought 2,000 Edesa Biotech common shares at $2.00 per share. He also bought 1,000 additional shares indirectly at $2.2796 per share through Pardeep Nijhawan Medicine Professional Corporation.

How many Edesa Biotech (EDSA) shares does Pardeep Nijhawan hold directly after this Form 4?

After the reported transactions, Pardeep Nijhawan directly held 627,813 Edesa Biotech common shares. This figure reflects his direct ownership only and excludes shares held through corporations and trusts associated with him.

What indirect Edesa Biotech shareholdings are associated with Pardeep Nijhawan?

Indirectly, entities associated with Pardeep Nijhawan held shares at several vehicles, including 372,702 shares at Pardeep Nijhawan Medicine Professional Corporation and smaller blocks at The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc.

Does Pardeep Nijhawan claim full beneficial ownership of all indirect EDSA shares?

No. The filing states that he disclaims beneficial ownership of the indirect shares except to the extent of his pecuniary interest. The inclusion of these indirect holdings is not deemed an admission of beneficial ownership of all such shares.